UB Paderborn / Katalog / Suche / in CDI

1 – 18 von 18

Sortiert nach

Design and Testing of Efficient Mucus‐Penetrating Nanogels—Pitfalls of Preclinical Testing and Lessons Learned

Small (Weinheim an der Bergstrasse, Germany), 2021-06, Vol.17 (23), p.e2007963-n/a

2021

Link zum Volltext

Verfügbarkeit prüfen

The Therapeutic Value of Cranberries In Treating and Preventing Urinary Tract Infections

The Online journal of knowledge synthesis for nursing, 1997-02, Vol.E4 (1), p.7-17

1997

Link zum Volltext

Verfügbarkeit prüfen

Interactions between comorbidity and treatment of chronic lymphocytic leukemia: results of German Chronic Lymphocytic Leukemia Study Group trials

Haematologica (Roma), 2014-06, Vol.99 (6), p.1095-1100

2014

Link zum Volltext

Verfügbarkeit prüfen

The Danish Cardiac Rehabilitation Database

Clinical epidemiology, 2016-01, Vol.8, p.451-456

2016

Link zum Volltext

Verfügbarkeit prüfen

High Karyotypic Complexity and Translocations Are Adverse Prognostic Features in Patients with Chronic Lymphocytic Leukemia without TP53 Aberrations Treated with Venetoclax-Based Time-Limited Combinations

Blood, 2022-11, Vol.140 (Supplement 1), p.842-845

2022

Link zum Volltext

Verfügbarkeit prüfen

New lessons learned in T-PLL: results from a prospective phase-II trial with fludarabine-mitoxantrone-cyclophosphamide-alemtuzumab induction followed by alemtuzumab maintenance

Leukemia & lymphoma, 2019-02, Vol.60 (3), p.649-657

2019

Link zum Volltext

Verfügbarkeit prüfen

Health Related Quality of Life (HRQOL) in Patients Receiving Chemoimmunotherapy with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) or Fludarabine and Cyclophosphamide (FC) for First Line Therapy with Advanced Chronic Lymphocytic Leukemia (CLL)

Blood, 2009-11, Vol.114 (22), p.3438-3438

2009

Link zum Volltext

Verfügbarkeit prüfen

Handbook of social policy evaluation

2017

Link zum Volltext

Verfügbarkeit prüfen

First-Line Treatment with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) Improves Overall Survival (OS) in Previously Untreated Patients (pts) with Advanced Chronic Lymphocytic Leukemia (CLL): Results of a Randomized Phase III Trial On Behalf of An International Group of Investigators and the German CLL Study Group

Blood, 2009-11, Vol.114 (22), p.535-535

2009

Link zum Volltext

Verfügbarkeit prüfen

Immunochemotherapy with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) Versus Fludarabine and Cyclophosphamide (FC) Improves Response Rates and Progression-Free Survival (PFS) of Previously Untreated Patients (pts) with Advanced Chronic Lymphocytic Leukemia (CLL)

Blood, 2008-11, Vol.112 (11), p.325-325

2008

Link zum Volltext

Verfügbarkeit prüfen

1 – 18 von 18

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(16)
Mit Volltextzugriff
(16)

Publikationsform

Artikel
(17)
Bücher
(1)

Sprache

Englisch
(18)
Japanisch
(2)

Erscheinungsjahr

n.n

Zeitschrift / Serie

Blood
(9)
Cancer
(1)
Cell Stem Cell
(1)
Clinical Epidemiology
(1)
Haematologica
(1)
Journal Of Clinical Oncology
(1)
Leukemia & Lymphoma
(1)
Small
(1)
The Online Journal Of Knowledge Synthesis For Nursing
(1)

4 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Design and Testing of Efficient Mucus‐Penetrating Nanogels—Pitfalls of Preclinical Testing and Lessons Learned

The Therapeutic Value of Cranberries In Treating and Preventing Urinary Tract Infections

Human iPSC-Derived Neural Progenitors Are an Effective Drug Discovery Model for Neurological mtDNA Disorders

Interactions between comorbidity and treatment of chronic lymphocytic leukemia: results of German Chronic Lymphocytic Leukemia Study Group trials

First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia

Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study

The Danish Cardiac Rehabilitation Database

Assessment of the Clonal Dynamics of Acquired Mutations in Patients (Pts) with Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL) Treated in the Randomized Phase 3 Murano Trial Supports Venetoclax-Rituximab (VenR) Fixed-Duration Combination Treatment (Tx)

High Karyotypic Complexity and Translocations Are Adverse Prognostic Features in Patients with Chronic Lymphocytic Leukemia without TP53 Aberrations Treated with Venetoclax-Based Time-Limited Combinations

Sequential chemoimmunotherapy of fludarabine, mitoxantrone, and cyclophosphamide induction followed by alemtuzumab consolidation is effective in T‐cell prolymphocytic leukemia

Genome and Exome-Wide Studies Reveal Potential Predictive Efficacy Markers for Venetoclax and Rituximab (VenR) in Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL): Subgroup Analyses of the Murano Trial

New lessons learned in T-PLL: results from a prospective phase-II trial with fludarabine-mitoxantrone-cyclophosphamide-alemtuzumab induction followed by alemtuzumab maintenance

Good Tolerance of Lenalidomide Maintenance Therapy in Patients with High Risk Profile Chronic Lymphocytic Leukemia (CLL) after Frontline Chemoimmunotherapy: Preliminary Safety Overview of the CLLM1 Trial of the German CLL Study Group (GCLLSG)

Health Related Quality of Life (HRQOL) in Patients Receiving Chemoimmunotherapy with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) or Fludarabine and Cyclophosphamide (FC) for First Line Therapy with Advanced Chronic Lymphocytic Leukemia (CLL)

Handbook of social policy evaluation

Immunochemotherapy with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) Versus Fludarabine and Cyclophosphamide (FC) Improves Response Rates and Progression-Free Survival (PFS) of Previously Untreated Patients (pts) with Advanced Chronic Lymphocytic Leukemia (CLL)

Suchergebnisse filtern